Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > KOD Kodiak Sciences > Key Indicators
KOD Kodiak Sciences
7.540
+0.150+2.03%
Post Mkt Price
7.510
-0.030-0.40%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-38.10% -52.423% -45.01% -47.205% -51.15% -39.599% -50.26% -31.790%
ROE
-35.24% -59.135% -52.54% -52.967% -58.91% -44.008% -58.75% -35.036%
ROA
-38.37% -42.390% -47.23% -39.003% -53.77% -33.165% -45.11% -27.084%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -- -- 19.06% -97.112%
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
54.14% 16.412% 54.39% 15.253% 38.57% 12.792% 31.55% 11.467%
Total Assets to Common Equity
14.44% 150.979% 15.06% 147.271% 13.25% 142.335% 9.93% 136.317%
Debt to Asset Ratio
68.49% 18.316% 63.27% 16.392% 44.17% 13.626% 34.11% 12.060%
Current Ratio
-43.93% 8.3028 -59.86% 8.6545 -66.38% 8.9369 -63.28% 11.3602
Quick Ratio
-44.25% 8.192 -60.13% 8.5615 -66.79% 8.7998 -63.33% 11.3092
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -- 0.000%
Revenue CAGR(5Y)
-- -- -- -- -- -- -- 0.000%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
CEO: Dr. Victor Perlroth, M.D.
Market: NASDAQ
Listing Date: 10/04/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist